Stock Alert for Cord Blood America Inc. (CBAI)
  • Stock Alert for Cord Blood America Inc. (CBAI)
  • Stock Alert for Cord Blood America Inc. (CBAI)
  • " />

    Stock Alert for Cord Blood America Inc. (CBAI)

    Cord Blood America Inc. (OTCBB: CBAI)

    Cord Blood America Inc. (CBAI) is engaged in the business of collecting, testing, processing and preserving umbilical cord blood. The Company is primarily a holding company whose subsidiaries include Cord Partners Inc. (Cord), CorCell Co. Inc., CorCell Ltd., CBA Professional Services Inc. D/B/A BodyCells Inc. (BodyCells), CBA Properties Inc. (Properties), Career Channel Inc., D/B/A Rainmakers International (Rain) and Family Marketing Inc. (Family). In addition, the Company provides private cord blood stem cell preservation services to families in the United States. It also engages in collecting, processing and preserving peripheral blood and adipose tissue stem cells that allows individuals to privately preserve their stem cells for potential future use in stem cell therapy. Further, it creates direct response television and radio advertising campaigns, including media placement and commercial production; involves in the placement of advertising in television and radio outlets; and production of advertising content, including television commercials and radio copy. Additionally, the Company engages in procuring and setting up call centers; editing, dubbing, and distribution of radio and television commercials; and procuring and placing print advertising, as well as provides advertising and marketing consulting services relating to the customer’s marketing campaign.

    The Company is headquartered in Santa Monica, California.

    Share Statistics (24-Jun-10) FY






    Q4 2008 Q4 2009 %


    Symbol CBAI Revenue, $Mn 5.8M 4.2M 27.6% 0.8M 0.6M 25.0%
    Current price $0.0053 Gross marg. 34.0% 55.9% 64.4% 60.0% 20.0% 66.6%
    52wk Range: $0.0197-0.0028 Oper. margin -67.3% -32.7% 51.4% -42.5% -626.7% 1374%
    Avg Vol (3m): n/a Net margin -103.3% 164.8% 59.5% -195.0% -641.7% 229.1%
    Market Cap. 26.91M
    Dil. Shares Outst. 5.1B EPS, $ -0.04 -0.03 25.0% 0.00 0.00 0.0%

    Source:, SEC Filings.

    Financial Summary

    CBAI announced recently that it has filed its Form 10-Q for the first quarter ended March 31, 2010, with the U.S. Securities and Exchange Commission.

    The Company announced that revenue decreased to $839,343 in the quarter ended March 31, 2010, compared to $941,938 in the same period in 2009. This reflects continued de-emphasis of Rainmakers International, CBAI’s advertising company, with total focus on becoming a “pure,” worldwide, stem cell company. Revenues from the storage of umbilical cord blood stem cells was up slightly in 2010 compared to the first quarter of 2009, which the Company said signals a stabilizing of the overall market for cord blood processing and storage.

    Financial Strength (24-Jun-2010) Company Industry Sector S&P 500
    Quick Ratio (MRQ) 0.20 1.05 2.09 0.81
    Current Ratio (MRQ) 0.20 1.18 2.51 0.97
    Long-Term Debt to Equity(MRQ) 32.85 18.56 133.54
    Total Debt to Equity (MRQ) 39.58 23.91 199.10

    Source:, SEC Filings.

    Analyst Consensus

    There is no recommendation data available at this time.


    No consensus analysis data available.


    Investment Highlights

    CBAI recently announced that Thomas Kolzau, an executive with a strong record of success in the medical, life sciences and bio/pharma industries, has been appointed managing director of CBAI’s 51% owned stellacure GmbH, the third largest cord blood banking service in Germany.

    Kolzau previously served as CEO for a consulting firm which advised on the German health care system and the life sciences industry in that European nation. He served as head of Sales & Business Development for IBP AG, a leading company in the field of assessment, development, and application of patent-based technologies. With a managed asset volume of over 200 million euros, IBP AG is the market leader in the field of technology development funds.

    Kolzau earned a diploma as a biologist at UKE Hamburg University. He has done doctoral and post doctoral studies in oncology and innovative drug development. He has also served as an executive with life sciences and microarray systems companies as well as companies in the bio/pharma industry.

    Earlier this month the Company detailed its new “Afford-A-Cord” program, which reduces the initial cost of storing umbilical cord blood stem cells from $2075 to $495 plus medical courier service.

    The Company said it believes the reduced price will increase its total number of assets, increase its customer base and increase the value of each individual contract.


    Technical Analysis


    CBAI is below its 13-day moving average. This bearish sign is even more significant because the moving average is also trending lower.

    CBAI’s recent volatility has been greater than normal. This is evidenced by the increased distance between the upper and lower Bollinger Bands. These bands measure volatility using standard deviation and a large width is due to high volatility. Additionally, CBAI is trading near its lower Bollinger Band. This suggests that the stock price is low relative to its recent price action.

    The MACD for CBAI currently indicates a strong bearish signal for two reasons. First, the MACD is below the signal line, a 9-day moving average. Second, the MACD is below the critical level of zero, which implies that the underlying moving averages are trending lower.

    Comparative Analysis

    Company Name Ticker Price per Mrkt. Cap. P/E P/S
    Jun24-2010 symbol Share, $ $ Mn 2010 2011 2010 2011
    Next Fuel Inc. NXFI 3.20 21.96M n/a n/a n/a n/a
    NeoGenomics Inc. NGNM 1.29 48.09M n/a n/a 1.64 n/a
    GeneLink Inc. GNLK 0.07 8.24M n/a n/a 1.03 n/a
    Healthcare Facilities Median 26.09M n/a n/a 1.33 n/a
    Cord Blood America Inc. CBAI 0.0053 26.91M n/a n/a 9.57 n/a

    Source: Thomson Financial

    Insider Trading Activity


    Inside Purchases – Last 6 Months

    Shares Transaction
    Purchases n/a 0
    Sales n/a 0
    Net Shares Purchased (Sold) n/a 0
    Total Insider Shares Held 0 n/a
    % Net Shares Purchased (Sold) n/a n/a

    Net Institutional Purchases — Prior Qtr to Latest Qtr
    Net Shares Purchased (Sold) n/a
    % Change in Institutional Shares Held n/a

    Source: Yahoo Finance

    DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority.  We are neither licensed nor qualified to provide investment advice.

    The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice.  The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities.  We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

    Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company.  An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report.  Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.

    Any individual who chooses to invest in any securities should do so with caution.  Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested.  Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.

    Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934.  Subscribers are cautioned not to place undue reliance upon these forward looking statements.  These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated.  Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC.  You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.

    We are committed to providing factual information on the companies that are profiled.  However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions.  We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so.  Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable.

    To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).

    We encourage you to invest carefully and read investment information available at the websites of the SEC at and FINRA at

    Leave a Reply

    Your email address will not be published. Required fields are marked *